Alice Park of TIME magazine has a lengthy article, The Quest Resumes, about the resurgence of stem-cell scientists and their research. Prominently featured is Harvard's Douglas Melton.
Jared A. Favole and Alicia Mundy of The Wall Street Journal write: FDA Panel May Reccomend High Fence Around Lilly Clot Drug, which the pair says will have ramifications for the multibillion-dollar market. Jonathan D. Rockoff contributed to the story.
Also:
- Federal regulators sue Solvay and generic firms for conspiring to delay cheaper drugs -- (538 words) By Matthew Perrone -- Associated Press
- FDA Questions Effectiveness of Dyax Drug for Rare Disorder -- (502 words) By Jennifer Corbett Dooren -- Dow Jones Newswires
- Democrats rally behind pick for health chief, imperiled by tax disclosure -- (724 words) By Sheryl Gay Stolberg and Robert Pear -- The New York Times
Comments